-
Posted by
Two Blokes Fri at 12:00 PM -
Filed in
Stock
-
0 views
For years, Denmark-based Novo Nordisk (NVO -1.19%) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors. Though listed on American stock exchanges, it didn't distinguish itself much in the vast sea that is the domestic biotech and pharmaceutical sectors.
